论文部分内容阅读
近年来病毒唑气雾剂用于不需辅助通气呼吸道合胞病毒感染住院患儿的治疗,被确认是一种抗病毒药物。此药活性范围、给药方法都不同于其他抗病毒药物。 呼吸道合胞病毒(RSV)疾病:RSV是引起婴幼儿下呼吸道疾病最主要病因、常在每年冬春季节流行、主要感染3岁以下小儿,需住院治疗的数字在不同地区约为(?)至1/1000不等。住院婴儿患病前正常者死亡率低于1％。这类患儿经支持疗法仅在几天之内就可好转,平均4—9天出院。但患有其他疾病包括支气管肺发育不全、早产儿,先心病、免疫缺陷病及治疗引起的免疫抑制的婴儿死亡率极高。
In recent years, ribavirin aerosols have been identified as an antiviral drug for the treatment of hospitalized children without assisted ventilation of respiratory syncytial virus infection. This drug activity range, method of administration are different from other antiviral drugs. Respiratory Syncytial Virus (RSV) Disease: RSV is the most common cause of lower respiratory tract disease in infants and young children. It is commonly found in winter and spring and infects infants under 3 years of age. The number of hospitalized patients is about (?) To 1/1000 range. Hospitalized infants pre-sick normal mortality rate of less than 1%. Such children with supportive therapy can only be improved within a few days, an average of 4-9 days discharged. However, infant mortality rates for other diseases including bronchopulmonary dysplasia, premature children, congenital heart disease, immunodeficiency disease and immunosuppression induced by treatment are extremely high.